We (Shareholders) Know Nothing. The Senile And Demented Raj Feels That It Is Beneath Him To Inform The Investors That Pay For His Salary, Bonus And Stock Options That They Have Actually Began To Sell Evomela! Raj Needs To Be Fired TODAY!
33 Days Later The Numbers Only Get Worse! Next Report Will Show Even Larger Losses As The Roll Out Of Evolema Gets Very Costly. The Daily Earnings Required To Pay The 8.66 % Interest Rate On The $120,000,000.00 Are Only Surpassed By The Stock Shares And Cash Bonuses Required By Raj And His Puppet Board.
What Brought This Stock Down Is RAJ. He Borrowed 120,000,000.00 Dollars At 8.66 % Effective Interest Rate And Takes All Positive Cash Flow For His, And Board Members Bonuses! Your Dream Of Biotech Wealth Is In Reality A Massive Loss Of Capital! Find A REAL Drug Company To Invest In. Mexican Cartels With Cross Border Tunnels Are A Better Pharmaceutical Investment.!
OH PLEASE! Stop Talking About The Possibilities Of A Company Controlled By Raj! What Is Most Probable Is The Continued LOW Share Price And Increased Bonus For Raj And The Board. The Game Here Is To Never Let The Share Price Rise To Anywhere Near The Conversion Value Of The Warrants!
WHY? Consider This, Rats And Mice Are Not HUMAN! The Real Clinical Trials Will Be Done On The First "Patients" To Receive The Drug. Their Survival Rate Will Determine The Market Share!
Did Raj Mention That He Would Have To Do A MAJOR Dilution In Order To Prevent The Warrant Holders From Taking Shares Instead Of Newly Borrowed Money!! Well It Is Only $120,000,000.00 At An Effective Interest Rate Of 8.66% Raj Has Made That Much With His accumulated Salary And Bonus.
The SEC alleges that Sanjay Valvani reaped unlawful profits of nearly $32 million for hedge funds investing in health care securities by insider trading on tips he received from Gordon Johnston, who worked at the FDA for a dozen years and remained in close contact with former colleagues while working for a trade association representing generic drug manufacturers and distributors. Johnston concealed his separate role as a hedge fund consultant and obtained confidential information about anticipated FDA approvals for companies to produce enoxaparin, a generic drug that helps prevent the formation of blood clots. Johnston allegedly funneled to Valvani the details of his conversations with FDA personnel, including a close friend he mentored during his time at the agency. Valvani then traded in advance of public announcements concerning FDA approvals for such companies as Momenta Pharmaceuticals, Watson Pharmaceuticals, and Amphastar Pharmaceuticals.
At The Least, All Board Readers Know That He Is Still Selling To You On Credit. One More Potential Investor In SPPI!
All Of Those Identities Are You Joe! Are You Informing On Yourself? Is This Another Attempt To Get 10 Cents A Post Instead Of 7 Cents?
Will Any Of The $15,000.000.00 Be Paid On The $120,000,000.00 Debt With An Effective Interest Rate Of 8.66%. Were The Changes In The Filing Necessary Because Of The Desire To Keep The Share Price Up While Selling New Shares Into The Market?
Send Her To The MIT Website Of Dr. Stephanie Seneff For The Search Of Causes And Courses Of Action For Top 14 Causes Of Death In America. (Which Is One Thing.) Then To Dr Don Huber Lecture "CFY Episode # 9" Which Is A 1 Hour And 46 Minute Lecture Which Gives Chemicals That Kill, Starting In The Soil Then Through The Entire Food System and Onto Humans And The Diseases Including Colorectal Cancer. They Will Find Links To Hundreds Of Research Papers And Lectures From World Renowned Researches That Are Not Behind The Pay Wall. This Is Not A BS Post!